

Table 3 **Antimicrobial regimen of infants with CRE bacteremia**

Treatment	All CRE (n =27)	Bacteremia related death (n=6)	Non-bacteremia related death/ Survival (n=21)
Empirical antibiotic therapy, n (%)			
β-lactam/ β-lactamases inhibitor	2 (11.1)	0	2 (100)
Third-generation cephalosporin	1 (3.7)	0	1 (100)
Meropenem	21 (77.8)	6(28.6)	15 (71.4)
Meropenem+ Fosfomycin	2 (7.4)	0	2 (100)
Meropenem+ Amikacin	1	0	1 (100)
Antimicrobial regimen therapy at sixth day of blood culture			
Monotherapy, n (%)	17 (77.3)	1 (5.9)	16 (66.7)
Meropenem	12 (70.1)	1 (8.3)	11 (91.7)
Aztreonam	3 (25.0)	0	3 (100)
Amikacin	2 (11.8)		2 (100)
Combination therapy, n (%)	5 (22.7)	0	5 (100.0)
Meropenem +Fosfomycin	1 (20.0)	0	1
Meropenem +Colistin	1 (20.0)	0	1
Meropenem + Amikacin	3 (60.0)	0	3
Duration of antibiotics, median (IQR), d	22 (11-27)	3 (2-4)	24 (20.5-29.5)

AST: antimicrobial susceptibility test

*Five infants died within 6 days after bacteremia onset, thus 22 infants included in this analysis.